Shares of Recro Pharma, Inc. (NASDAQ:REPH) have been given an average recommendation of “Buy” by the six research firms that are presently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $13.50.

Several equities research analysts recently weighed in on the company. Zacks Investment Research upgraded Recro Pharma from a “sell” rating to a “hold” rating in a report on Tuesday, October 31st. Piper Jaffray Companies reaffirmed a “buy” rating and set a $11.00 price target on shares of Recro Pharma in a research report on Friday, October 27th. Finally, Roth Capital set a $20.00 price target on Recro Pharma and gave the company a “buy” rating in a research report on Monday, July 31st.

COPYRIGHT VIOLATION WARNING: “Recro Pharma, Inc. (REPH) Receives $13.50 Average Target Price from Brokerages” was reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this piece of content can be read at https://www.watchlistnews.com/recro-pharma-inc-reph-receives-13-50-average-target-price-from-brokerages/1694431.html.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Wells Fargo & Company MN raised its position in Recro Pharma by 3.0% during the 1st quarter. Wells Fargo & Company MN now owns 17,200 shares of the specialty pharmaceutical company’s stock valued at $150,000 after purchasing an additional 500 shares during the last quarter. Bank of New York Mellon Corp bought a new position in Recro Pharma during the 1st quarter valued at approximately $156,000. KCG Holdings Inc. bought a new position in Recro Pharma during the 1st quarter valued at approximately $173,000. Rothschild Investment Corp IL bought a new position in Recro Pharma during the 2nd quarter valued at approximately $141,000. Finally, JPMorgan Chase & Co. raised its position in Recro Pharma by 183.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 21,784 shares of the specialty pharmaceutical company’s stock valued at $197,000 after purchasing an additional 14,098 shares during the last quarter. 65.25% of the stock is owned by institutional investors and hedge funds.

Shares of Recro Pharma (REPH) traded up $0.01 during mid-day trading on Friday, reaching $8.75. The company had a trading volume of 42,654 shares, compared to its average volume of 93,975. Recro Pharma has a 52 week low of $5.81 and a 52 week high of $10.17. The company has a debt-to-equity ratio of 0.40, a current ratio of 5.81 and a quick ratio of 5.23.

Recro Pharma (NASDAQ:REPH) last issued its earnings results on Thursday, August 10th. The specialty pharmaceutical company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.06. The company had revenue of $16.93 million during the quarter, compared to analysts’ expectations of $14.90 million. Recro Pharma had a negative return on equity of 56.04% and a negative net margin of 46.75%. equities research analysts expect that Recro Pharma will post -2.35 EPS for the current fiscal year.

About Recro Pharma

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

Analyst Recommendations for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.